Literature DB >> 15184390

Physical and functional interaction of CARMA1 and CARMA3 with Ikappa kinase gamma-NFkappaB essential modulator.

Romania Stilo1, Domenico Liguoro, Bruno Di Jeso, Silvestro Formisano, Eduardo Consiglio, Antonio Leonardi, Pasquale Vito.   

Abstract

CARMA proteins are scaffold molecules that contain a caspase recruitment domain and a membrane-associated guanylate kinase-like domain. CARMA1 plays a critical role in mediating activation of the NFkappaB transcription factor following antigen receptor stimulation of both B and T lymphocytes. However, the biochemical mechanism by which CARMA1 regulates activation of NFkappaB remains to be determined. Here we have shown that CARMA1 and CARMA3 physically associate with Ikappa kinase gamma/NFkappaB essential modulator (IkappaKgamma-NEMO) in lymphoid and non-lymphoid cells. CARMA1 participates to an inducible large molecular complex that contains IkappaKgamma/NEMO, Bcl10, and IkappaKalpha/beta kinases. Expression of the NEMO-binding region of CARMA3 exerts a dominant negative effect on Bcl10-mediated activation of NFkappaB. Thus, our results provide direct evidence for physical and functional interaction between CARMA and the IkappaK complex and offer a biochemical framework to understand the molecular activities controlled by CARMA-1, -2, and -3 and Bcl10.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15184390     DOI: 10.1074/jbc.M402244200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

1.  The CARMA3-Bcl10-MALT1 signalosome promotes angiotensin II-dependent vascular inflammation and atherogenesis.

Authors:  Linda M McAllister-Lucas; Xiaohong Jin; Shufang Gu; Katy Siu; Scott McDonnell; Jürgen Ruland; Phillip C Delekta; Matthew Van Beek; Peter C Lucas
Journal:  J Biol Chem       Date:  2010-07-05       Impact factor: 5.157

Review 2.  NF-κB signaling pathways regulated by CARMA family of scaffold proteins.

Authors:  Marzenna Blonska; Xin Lin
Journal:  Cell Res       Date:  2010-12-28       Impact factor: 25.617

3.  CARMA1 is required for Akt-mediated NF-kappaB activation in T cells.

Authors:  Preeti Narayan; Brittany Holt; Richard Tosti; Lawrence P Kane
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

Review 4.  Molecular mechanisms for adaptive tolerance and other T cell anergy models.

Authors:  Seeyoung Choi; Ronald H Schwartz
Journal:  Semin Immunol       Date:  2007-04-02       Impact factor: 11.130

5.  CARMA3 Is Critical for the Initiation of Allergic Airway Inflammation.

Authors:  Benjamin Causton; Ravisankar A Ramadas; Josalyn L Cho; Khristianna Jones; Ana Pardo-Saganta; Jayaraj Rajagopal; Ramnik J Xavier; Benjamin D Medoff
Journal:  J Immunol       Date:  2015-06-03       Impact factor: 5.422

Review 6.  The CBM signalosome: potential therapeutic target for aggressive lymphoma?

Authors:  Chenghua Yang; Liron David; Qi Qiao; Ermelinda Damko; Hao Wu
Journal:  Cytokine Growth Factor Rev       Date:  2013-12-24       Impact factor: 7.638

Review 7.  Regulation of NF-κB by the CARD proteins.

Authors:  Changying Jiang; Xin Lin
Journal:  Immunol Rev       Date:  2012-03       Impact factor: 12.988

8.  The protein kinase C-responsive inhibitory domain of CARD11 functions in NF-kappaB activation to regulate the association of multiple signaling cofactors that differentially depend on Bcl10 and MALT1 for association.

Authors:  Ryan R McCully; Joel L Pomerantz
Journal:  Mol Cell Biol       Date:  2008-07-14       Impact factor: 4.272

9.  Evaluating the expression of CARMA3 as a prognostic tumor marker in renal cell carcinoma.

Authors:  Guang-Li Wu; Jian-Lin Yuan; Xu-Dong Huang; Jun-Fang Rong; Li-Xia Zhang; Yue-Ping Liu; Fu-Li Wang
Journal:  Tumour Biol       Date:  2013-06-15

10.  IKBKG (nuclear factor-kappa B essential modulator) mutation can be associated with opportunistic infection without impairing Toll-like receptor function.

Authors:  Bryn H Salt; Julie E Niemela; Rahul Pandey; Eric P Hanson; Raquel P Deering; Ralph Quinones; Ashish Jain; Jordan S Orange; Erwin W Gelfand
Journal:  J Allergy Clin Immunol       Date:  2008-01-07       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.